RBQM and AI leader was shortlisted for its Time Similarity Test in the ‘Innovative Clinical Trial Solutions’ category
King of Prussia, PA – April 15th, 2025: CluePoints, provider of leading statistical and AI-driven software solutions, has been named as a finalist in the ‘Innovative Clinical Trial Solutions’ category at the 2025 Citeline Awards.
CluePoints was shortlisted for its new statistical innovation included as part of CMP 3.0, the Time Similarity Test (TST). TST enhances the detection of unusual patterns in electronic patient-reported outcomes (ePRO) data. By analyzing audit trail timestamps, TST identifies when patients at a site enter data at unusually similar times, signaling potential fabrication or non-compliance. This enables sponsors to identify anomalies earlier and more easily, reducing timelines and costs while improving data quality and regulatory readiness.
Andy Cooper, CEO of CluePoints, commented: “It’s great to be shortlisted for another Citeline Award. The Citeline Awards are prestigious accolades, and we are honored to be acknowledged for our commitment to innovation alongside other industry leaders. Our new TST technology provides sponsors and CROs with the ability to interrogate ePRO audit trails to quickly identify concerning data entry patterns, thereby helping to avoid costly delays when preparing the clinical data for regulatory submission. This new test further enables our customers to run smarter clinical trials and bring new therapies to market faster, for the benefit of patients around the world.”
The winners of all categories of the 9th annual Citeline Awards will be announced at a ceremony on Thursday, May 8th at the Downtown Boston Theater District Hotel, Hyatt Regency Boston.
To learn more about CluePoints’ award-winning solutions, please visit www.cluepoints.com
About CluePoints
CluePoints is the premier Risk-Based Quality Management (RBQM) and Data Quality Oversight Software provider. We are leveraging the potential of Artificial Intelligence using Advanced Statistics and Machine Learning to determine the quality, accuracy, and integrity of clinical trial data both during and after study conduct. Aligned with guidance from the FDA, EMA, and ICH E6 (R3), CluePoints is deployed to support central and on-site monitoring, medical review, quality risk management and to drive a holistic Risk-Based strategy in all trials. Coupled with thought leadership and consulting expertise to aid pre-study risk assessment, identification of risk controls and solution implementation, you now have everything you need to adhere with global regulatory guidance. The result is positive clinical development outcomes, increased operational efficiency, lower costs and reduced regulatory submission risk as part of the industry paradigm shift to RBQM.
Media Contact
Jodie Dixon – Discovery PR, on behalf of CluePoints
Email: [email protected]
Mobile: +44 (0)7507 727721
Office: +44 (0) 1606 889 194
